Axsome Therapeutics shares are trading higher after the company announced the FDA approval of AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!